Institutional members access full text with Ovid®

Share this article on:

Pharmacology and Pharmacogenomics of Neurological Medications Used in Pregnancy

CAMPBELL, SARAH C. PhD; SPIGARELLI, MICHAEL G. MD, PhD

Clinical Obstetrics & Gynecology: June 2013 - Volume 56 - Issue 2 - p 305–316
doi: 10.1097/GRF.0b013e31828f241d
Neurologic Diseases in Pregnancy: An Overview

Pregnancy increases the pharmacological management challenge of numerous neurological diseases as a result of complex physiological changes. Understanding pregnancy-induced changes in pharmacokinetic and pharmacodynamic parameters can lead to better outcomes for both the mother and baby. Although the application of pharmacogenomics in maternal-fetal medicine is in its infancy, further research and developments will provide important new developments for managing the efficacy of drug treatments during pregnancy and improving maternal-fetal safety. Although a wide variety of neurological medications are used during pregnancy, this article will focus on the drugs with currently known pharmacogenomic implications.

Department of Pediatrics, Division of Clinical Pharmacology, Clinical Trials Office, University of Utah, Salt Lake City, Utah

The authors declare that they have nothing to disclose.

Correspondence: Michael G. Spigarelli, MD, PhD, Department of Pediatrics, Division of Clinical Pharmacology, Clinical Trials Office, University of Utah, Suite 2S010, Salt Lake City, UT. E-mail: michael.spigarelli@hsc.utah.edu

© 2013 by Lippincott Williams & Wilkins.